Trial Profile
A prospective study to evaluate the efficacy of sunitinib and their relationship with immature microvessels in patients with clear-cell renal cell carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Mar 2016
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 23 Mar 2016 New trial record